Prothena Corp PLC (NAS:PRTA)
$ 19.88 -1.16 (-5.51%) Market Cap: 1.07 Bil Enterprise Value: 600.30 Mil PE Ratio: 0 PB Ratio: 2.13 GF Score: 66/100

Prothena Corporation PLC at Stifel CNS Days (Virtual) Transcript

Mar 28, 2022 / 04:30PM GMT
Release Date Price: $36.96 (+0.03%)
Paul Matteis
Stifel, Nicolaus & Company, Incorporated - Analyst

Great. Good afternoon, everybody, and thank you for continuing on here. It's always a pleasure to moderate panels with the Prothena team, Gene and Tran. So thank you guys as always. Gene, do you want to just kick it off and give some opening remarks on the recent Prothena updates and as brief as you can, so we can get into Q&A? Is that cool?

Gene Kinney
Prothena Corporation PLC - President & CEO, Director

You got it. Thanks, Paul. And thanks very much for having us. We always enjoy these discussions. So yeah, I mean, just very briefly for those that don't know Prothena well, we focus on diseases that are caused by dysregulation of protein, which takes us into two very important therapeutic areas of peripheral amyloid diseases. So these are diseases like AL amyloidosis, ATTR amyloidosis, and of course, central nervous system disorders here, diseases like Alzheimer's disease, Parkinson's disease and the like.

And so our portfolio is focused in those spaces. We have programs

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot